We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
The current TRML market cap is 322.54M. The company's latest EPS is USD -2.0713 and P/E is -7.29.
| Quarter End | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -24.08M | -16.5M | -8.97M | -3.42M | -17.52M |
| Net Income | -22.5M | -14.74M | -7.02M | 2.13M | -13.31M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -18.38M | -22.68M | -47.51M | -76.48M | -45.41M |
| Net Income | -18.16M | -22.71M | -47.83M | -73.89M | -42.12M |
| Quarter End | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 172.61M | 159.12M | 151.06M | 210.3M | 359.17M |
| Total Liabilities | 10.88M | 10.69M | 8.19M | 5.25M | 5.03M |
| Total Equity | 161.73M | 148.43M | 142.87M | 205.04M | 354.14M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 41.94M | 152.78M | 251.42M | 193.72M | 210.3M |
| Total Liabilities | 2.35M | 4.77M | 8.61M | 13.66M | 5.25M |
| Total Equity | -17.1M | -38.15M | 242.81M | 180.06M | 205.04M |
| Quarter End | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -16.9M | -31.58M | -39.1M | -28.08M | -14.92M |
| Investing | 27.41M | 36.33M | 92.26M | 3.84M | -188.87M |
| Financing | 46k | 183k | 257k | 156.72M | 161.35M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -17.66M | -19.21M | -39.99M | -60.86M | -28.08M |
| Investing | -562k | -133.3M | -96.39M | 55.67M | 3.84M |
| Financing | 36.2M | 131.12M | 137.4M | 242k | 156.72M |
| Market Cap | 322.54M |
| Price to Earnings Ratio | -7.29 |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 2.18 |
| Price to Book Ratio | 1.5 |
| Dividend Yield | - |
| Shares Outstanding | 20.34M |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 0 |
| 52 Week Change | - |
| 52 Week High | - |
| 52 Week Low | - |
| Spread (Intraday) | 3.17 (18.94%) |
| Company Name | Tourmaline Bio Inc |
| Address |
251 little falls drive wilmington, delaware 19808 |
| Website | https://talaristx.com |
| Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
